Replimune securities class action lawsuit

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announced that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. The lawsuit, filed in federal court, seeks to recover damages for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026 (the 'Class Period'). The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that Replimune failed to address study design concerns previously communicated by the United States — Food and Drug Administration (FDA) in connection with the Biologics License Application (BLA); that Replimune submitted data from an early, unplanned analysis of RP1-104 that included only 40 patients, approximately 10% of the planned enrollment of 400 patients; and that as a result, RPL-001-16 and RP1-104 contained deficiencies likely to cause the FDA to reject the BLA. Consequently, defendants' statements about Replimune's business, operations, and prospects were materially false and misleading. Investors who suffered losses have until October 5, 2026, to request appointment as lead plaintiff. The law firm represents investors on a contingency fee basis.